0000849146-24-000017.txt : 20240130 0000849146-24-000017.hdr.sgml : 20240130 20240130160556 ACCESSION NUMBER: 0000849146-24-000017 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240130 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240130 DATE AS OF CHANGE: 20240130 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Lifevantage Corp CENTRAL INDEX KEY: 0000849146 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 900224471 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35647 FILM NUMBER: 24578188 BUSINESS ADDRESS: STREET 1: 3300 TRIUMPH BLVD STREET 2: SUITE 700 CITY: LEHI STATE: UT ZIP: 84043 BUSINESS PHONE: 801-432-9000 MAIL ADDRESS: STREET 1: 3300 TRIUMPH BLVD STREET 2: SUITE 700 CITY: LEHI STATE: UT ZIP: 84043 FORMER COMPANY: FORMER CONFORMED NAME: LIFELINE THERAPEUTICS, INC. DATE OF NAME CHANGE: 20041019 FORMER COMPANY: FORMER CONFORMED NAME: YAAK RIVER RESOURCES INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: ANDRAPLEX CORP DATE OF NAME CHANGE: 19920406 8-K 1 lfvn-20240130.htm 8-K lfvn-20240130
0000849146false00008491462024-01-302024-01-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 ______________________________
 FORM 8-K
 ______________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 30, 2024
 ______________________________
LIFEVANTAGE CORPORATION
(Exact name of registrant as specified in its charter)
______________________________
Delaware001-3564790-0224471
(State or other jurisdiction of
incorporation or organization)
(Commission File Number)(IRS Employer
Identification No.)
3300 Triumph Blvd, Suite 700
Lehi, Utah 84043
(Address of principal executive offices, including zip code)
(801) 432-9000
(Registrant's telephone number)
_____________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Common Stock, par value $0.0001LFVNThe Nasdaq Stock Market LLC
Title of each classTrading Symbol(s)Name of each exchange on which registered
Indicate by check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company 
If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 



Item 2.02.    Results of Operations and Financial Condition.
On January 30, 2024, the Company issued a press release announcing its financial results for the three and six months ended December 31, 2023. A copy of the Company’s press release is attached as Exhibit 99.1 to this report and incorporated by reference.
The information furnished in this Item 2.02 and the exhibit hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
Item 9.01.    Financial Statements and Exhibits.
(d)    Exhibits
Exhibit No.
Description

99.1
104Cover Page Interactive Data File (embedded within the Inline XBRL document)





SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date:January 30, 2024By:LIFEVANTAGE CORPORATION

/s/ Carl A. Aure
Name:Carl A. Aure
Title:Chief Financial Officer

EX-99.1 2 earningsrelease_q2fy24.htm EX-99.1 Document
logoa18a.jpg
LifeVantage Announces Financial Results for the
Second Quarter of Fiscal 2024

Salt Lake City, UT, January 30, 2024, LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its second fiscal quarter ended December 31, 2023.
Second Quarter Fiscal 2024 Summary*:
Revenue of $51.6 million, a decrease of 3.8% from the prior year period. Excluding the negative impact of foreign currency fluctuations, second quarter revenue was down approximately 3.4%;
Revenue in the Americas decreased 1.6%, and revenue in Asia/Pacific & Europe decreased 10.0%. Excluding the negative impact of foreign currency fluctuations, second quarter revenue in Asia/Pacific & Europe decreased approximately 8.0%;
Net loss per diluted share was $0.05, versus net loss of $0.08 per diluted share a year ago;
Adjusted earnings per diluted share was $0.10, compared to adjusted loss per share of $0.07 a year ago; and
Adjusted EBITDA increased 289.0% to $3.1 million.
* All comparisons are on a year over year basis and compare the second quarter of fiscal 2024 to the second quarter of fiscal 2023, unless otherwise noted.
“We delivered significant year-over-year improvement in profitability during the second quarter as our LV360 initiatives continued to gain traction,” said Steve Fife, President and Chief Executive Officer of Life Vantage. “Adjusted EBITDA increased 289% to $3.1 million and our Adjusted EBITDA margin improved by 450 basis points to 6%, reflecting ongoing efforts to strengthen our core business and drive Consultant productivity. Sales of our TrueScience® Liquid Collagen product continued to be very strong, growing over 30% in the second quarter, driven by double-digit gains in the Americas region and strong momentum from launches in several international markets. Our recent annual Global Kickoff meeting saw high levels of engagement from our Consultants around the ‘Rise ERA’ theme focused on the three fundamental keys to success: Enrolling, Retaining and (Rank) Advancing. In addition, the next phase of our LV360 transformation plan is commencing in February with the rollout of the Evolve compensation plan and Rewards Circle loyalty program to Mexico, Canada and Europe. Our latest results further demonstrate the effectiveness of LV360 to improve performance and drive value for stockholders.”
Second Quarter Fiscal 2024 Results
For the second quarter ended December 31, 2023, the Company reported revenue of $51.6 million, a 3.8% decline over the second quarter of fiscal 2023. Excluding the negative impact of foreign currency fluctuations, second quarter revenue was down 3.4%. Revenue in the Americas region for the second quarter of fiscal 2024 decreased 1.6%, including a 2.0% decrease in the United States. Revenue in the Asia/Pacific & Europe region decreased 10.0% and was negatively impacted by foreign currency fluctuations. On a constant currency basis, revenue in Asia/Pacific & Europe decreased approximately 8.0% for the three months ended December 31, 2023.
Gross profit for the second quarter of fiscal 2024 was $40.6 million, or 78.6% of revenue, compared to $41.9 million, or 78.1% of revenue, for the same period in fiscal 2023. The improvement in gross profit margin as a percentage of revenue was primarily driven by price increases and higher shipping revenues, together with a shift in product mix, changes in raw material and manufacturing related costs, shipping to customer expenses, and warehouse fulfillment expenses during the current period.
Commissions and incentives expense for the second quarter of fiscal 2024 was $21.8 million, or 42.1% of revenue, compared to $23.6 million, or 43.9% of revenue, for the same period in fiscal 2023. The decrease in commissions and incentives expense as a percentage of revenue was due primarily to changes in sales mix, as well as the timing and magnitude of promotional and incentive programs.


logoa18a.jpg
Selling, general and administrative (SG&A) expense for the second quarter of fiscal 2024 was $20.1 million, or 38.9% of revenue, compared to $19.6 million, or 36.5% of revenue, for the same period in fiscal 2023. Adjusted for nonrecurring expenses, which are detailed in the GAAP to non-GAAP reconciliation tables included at the end of this press release, adjusted non-GAAP SG&A expenses for the second quarter of fiscal 2024 were $17.4 million, or 33.8% of revenue, compared to adjusted non-GAAP SG&A expenses for the second quarter of fiscal 2023 of $19.4 million, or 36.1% of revenue.
Operating loss for the second quarter of fiscal 2024 was $1.3 million compared to operating loss of $1.2 million for the second quarter of fiscal 2023. Accounting for non-GAAP adjustments noted previously, adjusted non-GAAP operating income for the second quarter of fiscal 2024 was $1.4 million compared to adjusted non-GAAP operating loss of $0.9 million for the second quarter of fiscal 2023.
Net loss for the second quarter of fiscal 2024 was $0.7 million, or $0.05 per diluted share, compared to a net loss of $1.1 million, or $0.08 per diluted share in the second quarter of fiscal 2023. Accounting for the non-GAAP adjustments noted previously, net of tax, adjusted non-GAAP net income for the second quarter of fiscal 2024 was $1.4 million, or $0.10 per diluted share, compared to adjusted non-GAAP loss of $0.8 million, or $0.07 per diluted share for the second quarter of fiscal 2023.
Adjusted EBITDA was $3.1 million for the second quarter of fiscal 2024, versus $0.8 million for the comparable period in fiscal 2023.
Balance Sheet & Liquidity
The Company generated $6.5 million of cash from operations during the first six months of fiscal 2024 compared to using $0.4 million in the same period in fiscal 2023. Cash and cash equivalents at December 31, 2023 were $17.3 million, compared to $21.6 million at June 30, 2023, and there was no debt outstanding.
Share Repurchase
During the second quarter, the Company repurchased 0.3 million shares of its common stock for an aggregate purchase price of $1.9 million. Through the first six months of fiscal 2024, 0.4 million shares have been repurchased for an aggregate price of $2.7 million. There was approximately $24.2 million remaining under the current repurchase program authorization as of December 31, 2023.
Dividend Announcement
Today the Company announced the declaration of a cash dividend of $0.035 per common share. The dividend will be paid on March 15, 2024 to all stockholders of record at the close of business on March 1, 2024.
Fiscal Year 2024 Guidance
The Company expects to generate revenue in the range of $207 million to $213 million in fiscal year 2024, down from the previous range of $216 million to $226 million, and adjusted EBITDA of $16 million to $18 million, with adjusted earnings per share in the range of $0.57 to $0.67, up from the previous range of $0.52 to $0.62. The Company expects a full year tax rate of approximately 22% to 24%. This guidance reflects the current trends in the business. The Company's guidance for adjusted non-GAAP EBITDA and adjusted non-GAAP earnings per diluted share excludes any non-operating or non-recurring expenses that may materialize during fiscal 2024. The Company is not providing guidance for GAAP earnings per diluted share for fiscal 2024 due to the potential occurrence of one or more non-operating, one-time expenses, which the Company does not believe it can reliably predict.
Conference Call Information
The Company will hold an investor conference call today at 2:30 p.m. MST (4:30 p.m. EST). Investors interested in participating in the live call can dial (877) 704-4453 from the U.S. International callers can dial (201) 389-0920. A telephone replay will be available approximately two hours after the call concludes and will be available through Tuesday, February 6, 2024, by dialing (844) 512-2921 from the U.S. and entering confirmation code 13743425, or (412) 317-6671 from international locations, and entering confirmation code 13743425.


logoa18a.jpg
There will also be a simultaneous, live webcast available on the Investor Relations section of the Company's web site at https://lifevantage.gcs-web.com/events-and-presentations or directly at https://viavid.webcasts.com/starthere.jsp?ei=1650314&tp_key=bd3485db5e. The webcast will be archived for approximately 30 days.
About LifeVantage Corporation
LifeVantage Corporation (Nasdaq: LFVN), the activation company, is a pioneer in nutrigenomics, the study of how nutrition and naturally occurring compounds affect human genes to support good health. The Company engages in the identification, research, development, formulation and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath & body, and targeted relief products. The Company’s line of scientifically-validated dietary supplements includes its flagship Protandim® family of products, LifeVantage® Omega+, ProBio, IC Bright®, Daily Wellness, Rise AM, Reset PM, and D3+ dietary supplements, the TrueScience® line of skin, hair, bath & body, and targeted relief products. The Company also markets and sells Petandim®, its companion pet supplement formulated to combat oxidative stress in dogs, Axio® its nootropic energy drink mixes, and PhysIQ, its smart weight management system. LifeVantage was founded in 2003 and is headquartered in Lehi, Utah. For more information, visit www.lifevantage.com.
Cautionary Note Regarding Forward Looking Statements
This document contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believe," "will," "hopes," "intends," "estimates," "expects," "projects," "plans," "anticipates," "look forward to," "goal," “may be,” and variations thereof, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. The declaration and/or payment of a dividend during any quarter provides no assurance as to future dividends, and the timing and amount of future dividends, if any, could vary significantly in comparison both to past dividends and to current expectations. Examples of forward-looking statements include, but are not limited to, statements we make regarding executing against and the benefits of our key initiatives, future growth, including geographic and product expansion, the impact of COVID-19 on our business, expected financial performance, and expected dividend payments in future quarters. Such forward-looking statements are not guarantees of performance and the Company's actual results could differ materially from those contained in such statements. These forward-looking statements are based on the Company's current expectations and beliefs concerning future events affecting the Company and involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. These risks and uncertainties include, among others, further deterioration to the global economic and operating environments as a result of future COVID-19 developments, as well as those discussed in greater detail in the Company's Annual Report on Form 10-K and the Company's Quarterly Report on Form 10-Q under the caption "Risk Factors," and in other documents filed by the Company from time to time with the Securities and Exchange Commission (the “SEC”). The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this document, except as required by law.
About Non-GAAP Financial Measures
We define Non-GAAP EBITDA as earnings before interest expense, income taxes, depreciation and amortization and Non-GAAP Adjusted EBITDA as earnings before interest expense, income taxes, depreciation and amortization, stock compensation expense, other income, net, and certain other adjustments. Non-GAAP EBITDA and Non-GAAP Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies. We define Non-GAAP Net Income as GAAP net income less certain tax adjusted non-recurring one-time expenses incurred during the period and Non-GAAP Earnings per Share as Non-GAAP Net Income divided by weighted-average shares outstanding.
We are presenting Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings Per Share because management believes that they provide additional ways to view our operations when considered with both our GAAP results and the reconciliation to net income, which we believe provides a more


logoa18a.jpg
complete understanding of our business than could be obtained absent this disclosure. Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings Per Share are presented solely as supplemental disclosure because: (i) we believe these measures are a useful tool for investors to assess the operating performance of the business without the effect of these items; (ii) we believe that investors will find this data useful in assessing shareholder value; and (iii) we use Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings Per Share internally as benchmarks to evaluate our operating performance or compare our performance to that of our competitors. The use of Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings per Share has limitations and you should not consider these measures in isolation from or as an alternative to the relevant GAAP measure of net income prepared in accordance with GAAP, or as a measure of profitability or liquidity.
The tables set forth below present reconciliations of Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings per Share, which are non-GAAP financial measures to Net Income and Earnings per Share, our most directly comparable financial measures presented in accordance with GAAP.
Investor Relations Contacts:
Reed Anderson, ICR
(646) 277-1260
reed.anderson@icrinc.com


logoa18a.jpg
LIFEVANTAGE CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(Unaudited)
(In thousands, except per share data)December 31, 2023June 30, 2023
ASSETS
Current assets
Cash and cash equivalents$17,331 $21,605 
Accounts receivable2,335 1,612 
Income tax receivable234 241 
Inventory, net14,972 16,073 
Prepaid expenses and other3,789 4,753 
Total current assets38,661 44,284 
Property and equipment, net8,970 9,086 
Right-of-use assets9,526 8,738 
Intangible assets, net389 455 
Deferred income tax asset4,618 2,991 
Other long-term assets518 569 
TOTAL ASSETS$62,682 $66,123 
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities
Accounts payable$6,237 $3,505 
Commissions payable6,798 6,651 
Income tax payable825 — 
Lease liabilities1,646 1,521 
Other accrued expenses7,511 7,932 
Total current liabilities23,017 19,609 
Long-term lease liabilities12,133 11,566 
Other long-term liabilities225 299 
Total liabilities35,375 31,474 
Commitments and contingencies
Stockholders' equity
Preferred stock — par value $0.0001 per share, 5,000 shares authorized, no shares issued or outstanding— — 
Common stock — par value $0.0001 per share, 40,000 shares authorized and 12,880 and 12,622 issued and outstanding as of December 31, 2023 and June 30, 2023, respectively
Additional paid-in capital135,490 134,314 
Accumulated deficit(106,992)(98,305)
Accumulated other comprehensive loss(1,192)(1,361)
Total stockholders’ equity27,307 34,649 
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY$62,682 $66,123 



logoa18a.jpg

LIFEVANTAGE CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
Three Months Ended December 31,Six Months Ended December 31,
(In thousands, except per share data)2023202220232022
Revenue, net$51,624 $53,662 $102,988 $105,436 
Cost of sales11,066 11,758 21,246 21,700 
Gross profit40,558 41,904 81,742 83,736 
Operating expenses:
Commissions and incentives21,754 23,556 44,227 47,369 
Selling, general and administrative20,065 19,580 38,027 36,310 
Total operating expenses41,819 43,136 82,254 83,679 
Operating (loss) income(1,261)(1,232)(512)57 
Other income (expense):
Interest income, net108 32 276 32 
Other income (expense), net41 125 (47)(312)
Total other income (expense)149 157 229 (280)
Loss before income taxes(1,112)(1,075)(283)(223)
Income tax benefit (expense)456 17 256 (225)
Net loss$(656)$(1,058)$(27)$(448)
Net loss per share:
Basic$(0.05)$(0.08)$— $(0.04)
Diluted$(0.05)$(0.08)$— $(0.04)
Weighted-average shares outstanding:
Basic12,612 12,543 12,574 12,500 
Diluted12,612 12,543 12,574 12,500 



logoa18a.jpg
LIFEVANTAGE CORPORATION AND SUBSIDIARIES
Revenue by Region
(Unaudited)
Three Months Ended December 31,Six Months Ended December 31,
(In thousands)2023202220232022
Americas$39,065 76 %$39,705 74 %$77,580 75 %$76,074 72 %
Asia/Pacific & Europe12,559 24 %13,957 26 %25,408 25 %29,362 28 %
Total$51,624 100 %$53,662 100 %$102,988 100 %$105,436 100 %
Active Accounts
(Unaudited)
As of December 31,
20232022Change from Prior YearPercent Change
Active Independent Consultants (1)
    Americas32,000 63 %36,000 60 %(4,000)(11.1)%
    Asia/Pacific & Europe19,000 37 %24,000 40 %(5,000)(21)%
        Total Active Independent Consultants51,000 100 %60,000 100 %(9,000)(15.0)%
Active Customers (2)
    Americas63,000 79 %69,000 78 %(6,000)(8.7)%
    Asia/Pacific & Europe17,000 21 %20,000 22 %(3,000)(15.0)%
        Total Active Customers80,000 100 %89,000 100 %(9,000)(10.1)%
Active Accounts (3)
    Americas95,000 73 %105,000 70 %(10,000)(9.5)%
    Asia/Pacific & Europe36,000 27 %44,000 30 %(8,000)(18.2)%
        Total Active Accounts131,000 100 %149,000 100 %(18,000)(12.1)%
(1) Active Independent Consultants have purchased product in the prior three months for retail or personal consumption.
(2) Active Customers have purchased product in the prior three months for personal consumption only.
(3) Total Active Accounts is the sum of Active Independent Consultant accounts and Active Customer accounts.



logoa18a.jpg
LIFEVANTAGE CORPORATION AND SUBSIDIARIES
Reconciliation of GAAP Net Income to Non-GAAP EBITDA and Non-GAAP Adjusted EBITDA
(Unaudited)
Three Months Ended December 31,Six Months Ended December 31,
(In thousands)2023202220232022
GAAP Net income$(656)$(1,058)$(27)$(448)
Interest income, net(108)(32)(276)(32)
Provision for income taxes(456)(17)(256)225 
Depreciation and amortization(1)
960 968 1,880 1,809 
Non-GAAP EBITDA:(260)(139)1,321 1,554 
Adjustments:
Stock compensation expense750 824 1,728 1,425 
Other expense, net(41)(125)47 312 
Other adjustments(2)
2,640 234 3,986 322 
Total adjustments3,349 933 5,761 2,059 
Non-GAAP Adjusted EBITDA$3,089 $794 $7,082 $3,613 
(1) Includes $116,000 of accelerated depreciation related to a change in lease term for the three and six months ended December 31, 2022.
(2) Other adjustments breakout:
      Class-action lawsuit expenses, net of recoveries— (84)$— $
      Key management severance expenses— — 100 — 
      Lease abandonment— 318 — 318 
      Nonrecurring proxy contest related expenses2,640 — 3,886 — 
Total adjustments$2,640 $234 $3,986 $322 



logoa18a.jpg
LIFEVANTAGE CORPORATION AND SUBSIDIARIES
Reconciliation of GAAP Net Income to Non-GAAP Net Income and Non-GAAP Adjusted EPS
(Unaudited)
Three Months Ended December 31,Six Months Ended December 31,
(In thousands)2023202220232022
GAAP Net income (loss)$(656)$(1,058)$(27)$(448)
Adjustments:
Class-action lawsuit expenses, net of recoveries— (84)— 
Key management severance expenses— — 100 — 
Nonrecurring proxy contest related expenses2,640 — 3,886 — 
Accelerated depreciation related to change in lease term— 116 — 116 
Lease abandonment(1)
— 318 — 318 
Tax impact of adjustments(2)
(614)(115)(917)(117)
Total adjustments, net of tax2,026 235 3,069 321 
Non-GAAP Net income (loss):$1,370 $(823)$3,042 $(127)
Three Months Ended December 31,Six Months Ended December 31,
2023202220232022
Diluted earnings per share, as reported$(0.05)$(0.08)$— $(0.04)
Total adjustments, net of tax(3)
0.15 0.02 0.23 0.03 
Non-GAAP adjusted diluted earnings per share(3)(4)
$0.10 $(0.07)$0.23 $(0.01)
(1) Includes remaining lease payments and other termination costs associated with lease abandonments
(2) Tax impact is based on the estimated annual tax rate for the years ended June 30, 2024 and 2023, respectively
(3) Non-GAAP Net income for the three and six months ended December 31, 2023 resulted in weighted average diluted shares outstanding of 13,221 and 13,082, respectively.
(4) May not add due to rounding.


EX-101.SCH 3 lfvn-20240130.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 lfvn-20240130_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Cover [Abstract] Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Pre-commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Document Type Document Type Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Entity File Number Entity File Number Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Registrant Name Entity Registrant Name EX-101.PRE 5 lfvn-20240130_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 6 logoa18a.jpg begin 644 logoa18a.jpg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htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover Page
Jan. 30, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Jan. 30, 2024
Entity Registrant Name LIFEVANTAGE CORP
Entity Central Index Key 0000849146
Amendment Flag false
Entity Incorporation, State or Country Code DE
Entity File Number 001-35647
Entity Tax Identification Number 90-0224471
Entity Address, Address Line One 3300 Triumph Blvd
Entity Address, Address Line Two Suite 700
Entity Address, City or Town Lehi
Entity Address, State or Province UT
Entity Address, Postal Zip Code 84043
City Area Code 801
Local Phone Number 432-9000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001
Trading Symbol LFVN
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( +R /E@'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " "\@#Y80"7$+N\ K @ $0 &1O8U!R;W!S+V-O&ULS9+! M3L,P#(9?!>7>.FTW#E&7"]-.("$Q"<0M2KPMHFFBQ*C=VY.6K1."!^ 8^\_G MSY);'83V$9^C#QC)8KH;7=\.$S=C/,:, .'?:4H"HK8'*: M&,YCU\(-,,$(HTO?!30+<:[^B9T[P"[),=DE-0Q#.31S+N]0P=O3X\N\;F'[ M1*K7F'\E*^@<<,.NDU^;A^U^QV3-ZU7!JZ+A^[H2?"W6J_?)]8??3=AY8P_V M'QM?!64+O^Y"?@%02P,$% @ O( ^6)E&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" "\@#Y87MF(SU4$ /$0 & 'AL+W=O<6ZF!SV5FUA(/M,DRY.$Z?<[ M'JM=W_&?6CW@<6R7@^.<@ZI3WM('' MQQ_JD^+AX6&6+.,C%7\3D=GTG:Y#(KYB>6R>U>XW?GB@ C!4<5;\)[O]M4'@ MD##/C$H.P4"0"+G_9&^'1!P%M/P3 ?XAP"^X]S5CNB[=6@9@^* M1RVB 4Y(6Y6YT?"M@#@S&*DMUV0&!>BY!O3L63<\Q-[M8_T3L;\S>45:](+X MU _^&^X"1LGBERQ^H=="6?X:+C.CH5I_UQ'M%8)Z!=O"MUG*0MYWH$FOR)\K9*OA:D/[E680T,:LGA/:].%AWR3-?"UM!8'QD22T8KO,PG8Q?AH^+X:TYZIC)4.E6:6<.\(',#?464)B.50]X@?2JJ M+2#Q:&2<]AVC!WL@T M@A**E0B+Q"%\#9(W])+Z?A!T/(SPR-J]F%U\') 'N(X\R7K'QR5; M+4K)0HL\23?D+MY&&&CE^QYJVSCH8J=J07')>2Z@=SN48H"5\7NX=7\/.+(C MF!@+M9.U<+C< ]\(C*M:"SS7"5)AZ_,GX?=^F9YI@53 9N=?N7Z/F[3"\TBVW7S]V2I M:GNN0>!A\O*(D50^[^.>_)$H,GX+-TRN^&PO9KEMW MDOSAR+DCO9*ZW="C<\W[)&D/1ZY8^\XT7'ND,E8QYU5;)VUC.2M;<%(R6=[< M9(EB0M-BK3MUIUQ+#J;3;D-O:%*L*Z//EI0&@U_*%">/3&[HEDFQMV)8RY20 MIV!>@N%@I+'$>2I\0Q=@:9\"O @:L!SC**&-!6,2,H3O_;C\&3!IK5>%E#/! M)0V&8MTPY[C5=UX9%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG>V)+;.'36-/+T08I:*Q[V_LL)BS6;_,C16/'DL\&D'+R!6TH>N77B<&GY85FS MX[V;IJFO<,[+?Y#SGZUSS36W3%Z2]J/_-U?Y+8R3\?1<'-&K SI;"5R$&_H5 M[E=YYD#VG9!.Z%$[BK+D^L4Y]>$=V_L+_"J^7U_RBG72[69P0\_R%UZ*3N7S MJGNHR[CJ+'^&^VB1S;>PSR5TR7M>;D?5UOM!)%[P6<<'')XC=\,31S"?@,41 MP+ \& /,)WAA>?ZG_:S0_00,X[:*(BO49X7Z!*\8LAT^6)ZX3^Z?^$[S/$VS M#*OH=AMEL,7JEF7P%X^&<0,/+ ]D>ENM\6[C$_+Z'& ]?6U"L)WBDXCM%*\U M(/&Z@4>>Q[N-Y0$/K O8[$#^>!Z8J;A/FD)7,6[8"<:1/,<0F,7XC&894IT, M/O'^8* \^>Q\ETWLJ.?]74_P$4$L# M!!0 ( +R /EB7BKL

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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 23 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.lifevantage.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports lfvn-20240130.htm lfvn-20240130.xsd lfvn-20240130_lab.xml lfvn-20240130_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "lfvn-20240130.htm": { "nsprefix": "lfvn", "nsuri": "http://www.lifevantage.com/20240130", "dts": { "inline": { "local": [ "lfvn-20240130.htm" ] }, "schema": { "local": [ "lfvn-20240130.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "lfvn-20240130_lab.xml" ] }, "presentationLink": { "local": [ "lfvn-20240130_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://www.lifevantage.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lfvn-20240130.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lfvn-20240130.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 16 0000849146-24-000017-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000849146-24-000017-xbrl.zip M4$L#!!0 ( +R /ECA64\I-CD ,GY P : 96%R;FEN9W-R96QE87-E M7W$R9GDR-"YH=&WM?6EWXS:6Z/?W*_!KM@UMBM] MYE,?B(0DIBA235*V-;_^W0N0%+5:DF6)I)"<8[NX@,#=<'=\&L1#[Y=/ T:= M7_[/I_];JY'/@3T>,C\F=LAHS!PRCER_3_[IL.@[J=62IZZ"T21T^X.8Z*IN MDG\&X7?WB8K[L1M[[)=TG$\_B7]_^HE_Y%,W<":_?'+<)^(Z/Y^YFMYL6+IJ MM7MFTS2[9KO=- V[06W#,FW5H?_2SN!5>%R\$\43C_U\-G3]VH#A]R^:^BB^ M?':=>'"AJ>K?SF:>B]E+7*.>V_7_7>*=6H\.76]R\?=.Z%+O[TI$_:@6L=#M MB=N1^[_L0D.P\'\^)W""MSW79RG<-!V!]<7ML3^I'],^(QW?#\:^S2+RF^M3 MWX;!R3V+QEX?<,QE&)D!3 L^?MR%/3 [\!WRWV,:PJ=)T(-% M18 F3J\+JQ S ^(,?UEQ+YUUE]K?^R' R:DE"^CQ_RYW78[ZVG(T'9<#%$N^ MT.^,7+GQ1"'?'I5TH@>=G;ET=N0H&JHR@_ "P$HA M>9Z["L)1$-+8#7QR?DNC91-]W_DX]-\_?K!:E^3+;W_>?E0()1[(:13Y(*^] M>$ HL-$S\SR?11&Q@^&(^A/R[,*=41@X8QND ^P-P.:P5\0!H78,.T',2#"* MW2$P7#(,/ RB)0+I0F,N2FP8<^S1$+[WQ#P%WG7HA(0,X(';3B^306%.!KGP M.Q*LW1/\_.^$PYGOP%N?F9$]R M[%5R7B;'(+H[%TR>*2"R#VXXN:!J^= M'9N9.'1^_-#2]<9E,=@;9C0+3,VL6PBI>R!P?\QP$_K!TNH- E_S@..1V1R& M>E;$;QKUUM](+PR&G#]&H0L$/V' (2.82^#4R?6+[8TY;^(#/NN#X'ABQ 6> MM&,< 5@$)N,3>QR&S+3U38.'@V2=T!%SZ EP; M,V\"TS'_!K357DU;>R&=]Q5O:RCD/3^\GA!KXF\)% M;CA]MA.Y],#6@H1,\/ M0+:60L"0BL81D&OR,$I+N--:\A858I'V@_7R26)RSYCL. @4P . WX>[:U"J M@>K-M<4PT0O35S-*$(\G:&[.(Q6%H$3LP1%[_>O-X^<."-A4?NJM-LA,Q. / M1EU+59?ZSJC9#XQ;&X'X/TC'\Q(J="/84 BG.#^EM0!DCOBK2R,WXOMN0K-\ MZYS;?7#GS.G? )+7'C(4,O8]-)P">#1\=D'1\P. \VKX'6$.5ZN4_<0OU M0&M [D7C#K=8L%DYM&H(MQJ'&^@4(?R+.PQA4X9_]-R8=EW/C2?$&8>I$C(' M)! 1P3@D7_XT&BJ\Y\8N5U'0OO1C%W9X+C+Z%!6E$"U*4);YS+1+$E'7(0\Q M: )@#?680KZ"@>@B$W/\70U)/$\@8U*5GJ6M)? M('S^#9S[_&N"RE. .*0[(::E)H0U"EP?+%<8"]6[D/4\!HL"V 1^/\#?K *% < MKA=??PS'[,%V0;5B>Y0T#90:&XB:('(1=Q0D!9?N:81%EB@*1, ME/M9BE<$UGPD"R<8=SU6<]R^&W,:CQ8,@I#U4UH3WR'# 'EL/!3VH4?'OCU@ M_,4(."$$<>.BC]7GBC/\"\CQ.XLC((>[,>K-MN /?PSW?O>"+OSZAVM_#WH] M,F2,TV)$G\D X"$<,IR"@! !$IR[^7>1HJ:$A^(4+04^=^0FK7%YCR+N^K[# M_]F\Q%M#!@:'/4:."L0ZXT'(X"*\2G%LF,MW-A'$/[;12R0\4N3:#P$7+H+Y MGL4 *9PF N7\GOK?/P(//J&/R._#,F\ 7+"Q<5&1V#TOP!J#Q+:>BAL0*'X$ MW#847K>11X%KN6<+YH*#(5!_8]T0W8C"T87#X4R",3>?\)_73X$'7(B[!?.C MW% XO7OV3$,G(E=N:'L,-)X)]4 > CWU0SK$=?[!7EP[4,@5]:E#^4O"^3-_>VNL21L40*OWW)1]%L2;IG;-M?Y. 71 M7R7^V\CM?VXH;,@\W*-@JGGA!>\U6\!)^&@"_5EWPP^F5F_//Z_-/I]] M';20Q,>.*)P1=\<);2X'W>. S1M<_3PT$Q,$H$5Q.:CR88QQNF0.R5$(5!?" MG'(J*5RS66;Y"#,#54'NI7%'(Q14R1@11NKZC*LC7#FB^$@O-?^XPCQT7P ; M ^KWA8H:@F:)E(X@X&.#/C+N ?,) Y%;!PQ-[RC&'2+](J 1U$8@8]SZ7E#/ MPJ\+3@[9( "5$C0CKP=(YO!(G\D;GH)5XS2$4EJV@8U]Z$:1RYT8/M(IHI?; MS,FRMV$F7:NW9IC#U.>98X:9@!-FF<\TZNWL^0*QR,9\??B-%KDWB_;!=.S7 M,?H*)SMCEN-FY)8IRT7<"< 9$9[$^#W^YMN+.TS-J"'MPZ8_=OC(P+S#(+$> M9^:3VBW1FC!Z/AEKT>I?E9Z5<)LZ?85VHP"=R0NOK,S0R?\F")'=\'4S5,*(PZ@ &7F[-(9NZ7S%V<"+-?YWB NU7<\5'H68=CW.SV@MH-8H4F<8^B#1 M#X&NQ1!-?V UE"O*-,R2#9E"=;H];@A5%K(B:3\_:,VZF6+L\.*;TTB!P&%P MZQW)]0@VXQ*&VA?A&20H$)1[7%"8\X)B1E8,2_$4D,5< M@CD),YL;HLWM]ZN219;&8UZC..[;W(SJ<%*X&=.7912(=]]$>^G:-/55^"Q\ M/$>.K058-9? JN*D.A^SY;#.!W$5(2*CPJ#<;4^Z?]>OD(D(XSG^-?393.6$(?QMZ^[C/H4"J&8@YL*>Z('S' M,;KE,9I2/T+60 DH?T7\E(O\>S8:AS:&R4NPD.4H^+PJSV@A)IJLU"%J3GWE M6Q_G6*PN0;<<7L2X.!?J&-/O]T.,&P%S)B,D'G.AAV2J7IV0QP%P0G^PB5!0 M2%X$)+,8T"=&NHSY,]-=G$?V>7VJ2O'/)XPZ%V#Z03=S6GC(ADDR!3!M$O9- M'>73SV;Y"G0<#X+0_5_ADZ!\'8L1*8+_O2,-';Z>3!"7^X3)94Y6'BF*6E*7<9)UYXDZ1I"1T]9!"FV3KA? M.WWP&2@,4Z1&F*0'S_Q!@9:(9BE9RB2%!_)))\*0MH,P\V[9H+9RVLZRWJ8# MB7'>8'$7@ZB27)7_P11*#IC?08NBN1R],A#6@OJ$?AY;)#&FFE0^-,ZSJ#! M(>26FLFM1!4Q\NI0(BSW;A_N99]9]+[]EW MM)R=)**;2S/>9RS+Z0S4NM7DPZCU1E,AX]':^<+3>OJT+F3W B@I!C@3,("% M23A,D4%GI+NN\SQ5'=-5'M$IW$_(*4TUC69$/":8.EG28'H67>@P3XKA[4D6108*3=7OW(XZ MLP1,Z@-K'7UX;\GW M1Y)^5X'?8P)J5[@=W/A9.F9I== \X?%-$+[9K9J&U[6JH9%0?ULD?#X_DW)RY=/WP^+$.4!(#12+3EW&.PZ0+BJ%#=Y3Z.3E) M8>J^^ P2D(.T>MYJ-C^2IFK63-,RII+I6_T!!\\G#^.+N#5/W]55[2,Q6NV: MVM;5.ND0D#ML-$"*!X71HY-LYZ=/U/6X^V-61L7/ FIL.2M6:MT6@F \VF6'N!G28U;CCP:L:5 M\?/CQ,\/68J"4!!>MPR)/I&>@&BF#;9]8%[3O.L4"2-I]* +#9 MO<0%%3$[U=GCF=T;!H&Q05D ?.*4Z37V_M2!W$\$DG\/!>2__#<'GM*BF_Z M=@0#=.M@2?![J"3&40W8J(;Q;$QW$>L[?#^, !4!4$%B;U(D(9 M40:W**:\,(#5_XI&/WYH&)?,A5_:I=:P5$,SN9,V'OWK.YOPRUW',%N6T[7V M60RTX;J$+J55:];U MJIGO'(,"*.G^DL5,?=BO79[%!I<8;/N@G_CC.'3!0 R&KAV)UZ)X[$Q0B V" M9W$_3NN?8+L=AZ G3!)E6^RPPQ%JK:A+8 $,&8R'H*J@T9E4$8VP_('T@\!) M^L_,F@:BKBDS@7CU(*]P%.5#*(*0,,'HQ%*H8(0^'YX/!,*:9E/#'#MNC/$R M)+1_B;!44( "0%Y[ LIS>$!DR0K2M*2(^TU['NUCYB[Y&@;<&S^4]8:O M1 [$6$GN)4?.3',H";]7X'1>RV7[3)'R M_IFT]5((+]OL_(%UEA&+R=<_A!#Y;/R_Y;(+I:8L+=Z<5#/Y"N);X;+[+6); MV ])B:_8B@"3$?G*I.3=C/Z32!\ DQ?N LE/R3O;YT60'!X#3!'02QV1IXP% M^A'7'9R@#[S0>7&7IBQ*B.<8P.6Y4XG"0S ZT.<%2/YW+%)(ZWJ^#B;1S7\+ M]$1 W_&B"D2B212S87U&U<: 9P\U0N$2TU75$#4,$:I_3A(.%C>_L(&KD&\Q M!9WPM]1=ZTY=D IY<@&TA[7\.)">GY_K>2L9*._PF-I?;.V=GMXWHB976O&2E M4;928!B'9RM$8RQ835O5T!Z#S2?L MGSL(BH/DJ<1U]#T;CS >,O(%M L?\" MO_K"X+EGR"&D(XJ\M7;;JF/;9T?L/^R%UR'PX?+M3; 'J!L-P6Z!4:(>3;Q5 MZ&.)P-K'MBA\23S6EM7JA4'$PU\SM4O/_&/1&$LI(MPWS(, ?J*AF_C$N,,GZ"FIV3I90P>@98QY5!V, M1=J->/0A"S,-&?5%:(U.7TG#9G-C)G'^7)H S(K[H)"6Z(2_RC,'LER )#Z' M^DJ:2"EBEX(;[;TQ&/K35((HRSS+5ZS1(6;I\D2:AQQ@DWSG(BSX3A.YL1<4Z%S8V2. R4?Q=!CQT2"C14$& O)KA7$+_G]' M87PX67/]0H>CI(/0&@&3&/^"P"B/>,:@Y@Y=H38I^6>?&'% MR(!!@$;6%F;:J.+J[L^;SS6MC>YU_%(:"%<2I,\T(<[U45%2B2>>R>@]X0*N M&2:33.@>M/<'E%MKP)E"L ]O +4R ?_Y[BVS/GXLH,[U1Q9T[[B]'G!:&B@' MLD]B8)A4D^P<0A'BHG0Z!<[AHN9NW22[--?(9SJ79?S"I\QE=(]W]K(9C[:G MP!%._\2%ER;P3=.3<(ZBRGA2MC7_P-'/P]2J[ J+@FOE]E>0(VQ>+P MM> "N16,8\S,CY*^3CF8"2AF?8\$]*:BW1&]=-S('D<(#I3(KI]"<-7L,I8! M*8:;(PIR3M!I_1 F]8JIFW0*RHYH)'7/N\P@,?R&NH&FUOZQ MA$R3!CT U<7G_SN?@4A'?.5\*[P'&)+? &7H/Q6;HR ) ;9,&0(EB!=4=F>S MVP36,.$"X8B_LT9..?6&MUUZ$5739%IA3\[3AE:P%S]<7R7[\,=9&]P6"FB4 M1?C%OHD[BD>!7V%A8R9R-WA^B(#A&NZ:81_#31DS9\ND;(FQK&E M/9@!53(Q=/.25+.80Z) 4@PBG._<0==+M4(8"Q.;(I[X,AXY26.J]6*$O\1U MQ%0&8'J$&\)B,9$;3Z"8Y@@X2<;3#$!01-ML%!/>A^??8S<4).#1YU*%BV[3 MA*GIB1M_, IZ$8O*D%>^7('@O2-[Z/"ZG4\6BZ895UVT)UB6RY(F1BEIM51, MN5? 86!8V.XTZ *R,XRS7&2XD'UDOKIGWU]3DJ3PF9YOV4!"+(GA>%&8X*)$ M_B>W&%/I25(PD*^&P$. -U\]1KO8IJN!E,19[+^ICE["YEN. !*(2=?+Y,4N*$V >RZ8G5"Z^,$&)S*E1[(((8CS-YE]2%%)&3D(H)"D1"+LYFE%6 M$HRR'*]+X?TU@W>7"<4IYVY+;.Q$MP+<35(K+NNW"%(+DX.0&I]<]LR5Z5R9 MU#.V,L7>6? .D@'?B;GUA0\F;0^$3I;N._-M$((<)::9D\\LRY/,S$HJO'DR MS:I@:59E83@4D!ZHX4+A205(:HIF]0C "GYB;H$\#KJ)VL8=+'&BJ8 Z[04H MB!<$_;Z9-BDX3NEFTAHMD^/-P; M8\)JX(E#>#*%-^9N' $2EK-+\G9KXEW,@(?L'XSC7/_2Y!%LBP0J8B3:OY^[ M\S.C<>[+/'\(]B\G 3>-LWGR%F@X*:YV#GBK,"PU$5U/L^;R^ 7Q"91X[XRC M)'/4$YCI,M\>8/B.0Y#AO+B6.Y6;\S ,L[[D^%#^%M?F:9S2*%=.0!,(PB1D M.!:U-.^RONE&/:"19I#)MF ]$*22]*;'F#<*QW M\Y)\VZ?,:L%&-Q@?$?M&,@@N,*>J #.($E>D!!M+BSBD^+Z#KRGI%_+OS[8N MAP>\M+2YO/H#XC]I(811?6PQ/D"&"IY3@3&WTT;O3RKY=DA9O![ M;M!E8R')#P/NP$UR-G/:\9)1IW)R!6V4 =G++*ZN;HO7#QR^<3/&V;C(]&;S9JF-]1RS#D$8-=I NP?/S3,2]<& M$\W.1YX+JD,[&Q\@:YY)O7O9%/G&,$5/"%2 56 >'47L(OWC$O1&+.^Y<'U. M/ORE72;8;M=;%J:!?XH!K;&3?C@!:IT#]:?86;S7T.M-;?5MM:ZMO+=N6*U1 M;^C63L.NOV<9K?>9;'.C87_B\!4P!BQ&(^K_?*;I9U/2Y\?_7 "A$6VTY)C> MA>0ACL;-Y=*CBQ&56_9,[@-045=(J/9K>QIGLR\WOUW_V;E][/Q^3:[N[K_> MW7<>;^YN2>?V,WGX]NO#S>>;SOW-]4,F)RH'@:N[VX>[+S>?.X_7G\FOG2^= MVZMK\O"?U]>/Y5XT'_ "%&[/M=?O5!P,Y]]\.G8PMOSQ]64;FZP:C[\J^)IO M,#(3C&%0)\HB'M/R<[1Y9Z&Q-1"*1^\+?46V6*"*RSNK#BRP&Q-)&S%M0_:+ M==VVS5BO=UDL?EA+_9V'AWD9M^5B$YT&%6M8*SK&7(>D\]Z"9EZ%YEO&V'Z2 M6^,^J>DO$>ZODF02=./ELC:W >_O)DM)BO MF!3F.M.T=%Y)A6GQIZ7*&$JSU9;*3*%Q9"I-:ULA5E!UQF@66"8\!I@:;6\6 M;=A@O]PHF%,>,C1:2J.QK5J]+2A*I Y5#+VFJ>BM;>W:0Z$WD4%SZ7$B0?(( M8=I"CW$RYN?7$,LC8M$= ,.(26/.D[-%6V"*JM(4+32.VHK::A36$JV.87>/ M?]>"7@TKG=Z@PY766F@KEKXMH4F+[M "NVFTJF'1%5H8W/@Q]?LN/WZ$BX(3 M5 Z,K?T[4C4XL.5E'3&WX&04@\^LQT)1!IP%L+E0."WUP%0:VA&W'JD>;)1N MU&X7-WY=@:A56?69.]ZWR0O\?BUFX7 //NKR,8>UM?B2^LR!,=0XHL9Y K50 MCW>/G2]D>4747@J,JIO;QYOK!]&NXO'N MZA__>??E\_7]P]_)]7]_NWG\'[)2D9V8/%T@MVCQA4&N//DMLJ"TL<.6?L0M1T9W-\ 0GA^EZ9=2 M,7A_IPNC$=O((J_DEJ,I#?.(*<=2+=@(1Y8NU8)#94Y0VP[';%KU>UJJ05.Q MM/)W:*LZCMK&CH%=F?IU.L7)>])I*E;"JAN*JFWKX]T6%"52ARJ&7JVM--0= M4\M*D2M0AE#N <+!I=MEY(3EA"N8TO ERS/W3MR1HBN:<<0V8M*3L@F2-,5J ME+_"OL@"8;[\Y*T"H;16NBZ#+$7'4/N(7>U.S"DAG1%+LW\LQ6CN6-@MG1'% M1Z^FF,V"MTNKLB["D[YB;/@E>K?:\ 9,G?GVKIG7\IRPDMNK#W%@?Q\$'AY@ M_'?>$"Z>[%93L:G8DTGX!T#KUS#MW!$A@DF2/T-&-"1/U!LS\H-:AQEHT\,P M%6(I<$7\ ^3#.!X$(7S148@?I%?=*,)8.RK0'UZ]JM"X%LC9L?N$_,F)^:*E5Y8B9\3SV7KP'QC-_"I1_ ,BYKK$YN. M\"#QT])>-,-2S/:VC8^E]G)H+)F*H1WQP+23T5XZMCT>CCT:@X;AL)YKNR?6 MZO1<4QM*NZU_E.I!43'4;BF&:AT%0:>C'^3D #_2"I8['(5LP/P(3 ;B!=&) MQ6O/-47;1BQ('>'@^#$:VE'PY="MZ%^ZKB-:*IE$7[0=^P**)2YK0B=;1^X+/H7F\SUT2=T# MC K>,$HRBV26/35B/2*S\%WSIQC;O>&\MF?LS"!,2_?.KB M:\EBY]]*P-/4 7ZC(.(N]XN0@5T-1O3EL^O$@P1V^;<2(*C35V@7UCN.%U]9 M.8G\ST%64C:B?5;KAHQ^K]$>+.*">L]T$LU^?NCZM?S$5TUS&4C<89]0+_[Y MS OZ =5:M/[7J ^2)[07+LU J $8NQS2L _?3I9OC18-'_RBN)W,2F\W1R]G ML\O='6NN\_.9J^G-AJ6K5KMG-DVS:[;;3=.P&]0V+--6'?JOYMF&7^*T-$4J MIU^@>H^.(G:1_G&95@:Y/NTE;?5^NI[ZX;5M'K36GU[W;#K[UE&2TZV7).U-AIVJ>&BFV=3\;720!%, M=YC=4%/GML/F\MJWF]^N_^SWC [G[C=Q]O1;P*/GZ^8@7&#EW M[4W^PYR9Q+$-\ITK"YH']V5#P&Q(/$)-,ODK!3E]'S*EJL"1 M9+4?LBIUW&-AT2O.IF=/S!^SI8=0;^AC*[P;=D-05.^\JPT7;FE*0]\Q&[)B M,0=)RV6G94-I-.0QA)*6*T#+FJHK[=:.)Z-+8I;$7*2%:ZJEF,:VS; .?*QF M.5L1;(B!JR"*L:8SHEYUNN5M2GV:HAZS$]N)5V)LCJ6F)4^-*CB6=$W1Y2$> M),KX;<$.8E;N]^='*.88YQ"X/9NQ$** M[46SD^-^_&"U%AAYKT)2CE&<,2K00F9CO^7T+'7L/N?ZF#SB/IV<$Q-->FO' M_L[2\7(P+!E@]DKW6,&Q9)J*KN_83T%BZ6!8:BI&8\>V"-*)N0VD'Y@'%_L* MZ3,?%$N/[[34&;J^&\4AKR^M2G^F3>6XJJ@->:9.P;&DM16K)?MM%AQ+1DM1 MM]YM)98.C:6&8FA'Y*4*]#W;$-*B\5FPX,(YB89GFX>76EI16V(=07VO''X- M1=LZ_"#Q6QK\MG1%W]5;)?%; OP:2J-95/E\6A&@@"DME&&+NY[6G$,@OBT)J/+I.^"HZB<[,I M#TXL+G:,'=RW!RR]2#JJ)6 M;5H2M55$K=XR)&(KB5B]@(@]I3!XJB: XN"SGAOOQ]=00E(T94>'HJ-(D]T< M"HXA73)1T5$$6^X62G+Q8N&%-L%O64RP4D>>L_5>ZR\XZE4(M! M3@,@[P3CKL=V.I'Y/0O@Y"R/.LO3R1C_E4:N_98DPHKN767:GM2ZNGW$M41Z ME"2W(JT-R6U[=4B2FR2WG=;VXX>6KNF7I2\5D517)JI#(6>6N;BB!*KG9]<; MQ\QY2Q2L:HRR;(G%9Y3C1#+W9$E*.534IVDN@,JGS([ M:"OH_I/_@SDU"K.B?2;B"A$)QG$44Q_7(?NMG=(8IV-Q+77V5SS34M.5AB8[ M>!4?2Y9I2"P5'TM->3!J";"D;GN\5/&4R!+LIRL\F!O15WG[#NVTHQ8O(%-] M+&V_HTHLE6%'E5@JPXZZ[YC@3S'M>@Q^.^[3+Y_X#S&3+MY,)I7>2Z>5+*.I MPSI'0>3&;@!?9!X_:/CRV77B0;+&_%OBZQ?J]!7:C0+63F)_$\H M#Y0#FG8AV\G,+-&B_H)?E'<3F:EMYNCE[-%&*V9(D?^%#\\ MHQ$(S:.CB%VD?UPZ;C3RZ.3"]3D1\Y=VF6"[76]9.D(NT>.2#R= K7.@SG% MLC2CKC?UE;?5NK;RWKIAV_5&:[=1U]\SVJN_N>MS\?DVN M[NZ_WMUW'F_N;DGG]C-Y^/;KP\WGF\[]S?7#C":U\_M+"\9T_, M'S/2G9![U@=-;!G0RK-6/N*%&\/7[$T"H=]\.G;$_#D+&R!_PW" BU[[#'/*9V6S892$Q M-&6#X.S)@N[!?=D0H^6NUY(MBH8K/8%*"K MNK%)^L(F"U[)/A4%G+X/T5)1V$BBV@M1G4*656<([]E4]F ZT9X)1EM1&SL> M\%.T_A]O$VDGV%!VZ^/X#H#X8\#A;^^10RHEZ,E(T*8J)>B)2M = OD[YGA76X*> M0MO-3N32'S^8S24G(;*6DHC:VU5"DEI9244E)*R9.1DIJJ*^W6MJ:B%)-23$HQ*<7D M"8E)2S&- I;$2#$IQ>3[^U+32>RE2\?2.N.WG3TKORF_*;]9[39*'1O[79*. M;8,4CJ/70SY%7BD?L9A-E.2C\M&C/"K;:*T0?!$)>GOOG"4??6=RK&@;'-D_ MZ)A-J39J[%:\Y5\-J-]GI!<&0_(U=(.0_ ^CX0D#Y"L+<5)$ *:T\OS0J599 ML_I#>T42X^/&=]B(P0]$7>!'8R^F8(N0%(%[G5JC;FTPMR5' J"\K!GU)5WB MNS1B. !8%-K4DA =[ ]>CGD2'RC%),O_ 3G)]_,\%7D_*6%AK@@S+/Y=/4#5U1CWG2G2PFV 1+C>. MYR8R\4*7?V@$Z5O8--7F MW8K8-!4*RJSZR?NOD/59 6\)Y%2MO,;2=G<0%Z9\:H_>IZKA=_ORJ0,@MZAB M7E+65D$+*3FJC%\I.:3D>"?#HKU3/$L*C1*@5K/JQ<)L425&H4W*])E-ZA9+ MD54I)RDG*2YPV9$E5L M!+7J39D352G[I4(Y4?)DZ5STNBD+7XN/)5V3A:^2/%:3QQM2C"03'PQ+QSEQ M5#)Q.SAK)*B5$S),>08 M>QJCF(^>=&K4:9[AT;9D D7QL=249WA(\ECGK)5<7 (T->4A'I(\UGI/91Y4 ML3'4KELR#:I2%DR%TJ#D(1Y3&.UTJIDLECMT7K@\Q$.2QVJ8F?(0CQ)@R9"' M>$CR6*,SMV3%>K$1I+7JNBQ9KY154Z&XS$;%'6F$7)[;D7,*&_+@CFHCN(C( M+:I@EY2U#669NU1W2-%1'@07$;E2=%2 LL":D$=W5!:W^@Z'V)^BR"BT&9D^ MLTEYQS9ID5,\&X!))QAW/?;.2>?RF_*;Q^:JM_IQS-;"2V7PUYQK'\DKIZB2 M 86;HW%H#VC$'#(* V=LQ\3U23R &Z$;A/!7R!@9PO<&$>G!A9#%U/4(_#5B M813XU -8P9C#$98?U&>D;Z4 JD\!.CW-8R<0+@,<"7QO4F'H&0"]I3Y!XD8< M5@ ($O36DRRAZ4O4=^:1D=U< L6?8@J2*BURR0J&?OG4Q9O)T^F]N0VXJ<,* M%\MKGETG'B2KR[\EP'RA3E^A75"JQO'B*RLGD?^)0[O.SV>NIC<;EJY:[9[9 M-,VNV6XW3<-N4-NP3%MUZ+\TXRQ]:1!.B:3/:MV0T>\UVHM9>$&]9SJ)9N<\ M=/U:?K6KUI:C,!LPPT*X[0[[A'KQSV=>T ^HUJ+UOT9]H-'07K@T ]8&D.WE MD(9]^'8"LR6E2OR+XG8R*[W='+V<+<)HS10Y\N?V,"!\CXXB=I'^<>FXT?BGFG53;VU\K9:UU;>6S>L MIM6;UNK;ZX9=?\\RY&3?9[)&>[=17YUL8Z-AE^X\NKG)SB.8[DA[3W/IWO/E MYK?K/SNWCYW?K\G5W?W7N_O.X\W=+>G.&"-N+:FR@OWWPZ=EQ8_<=EZYXWV,VW&.SM=S%\7AGUE0#V M#L,7!M5KV>*1:^9_",W\&K1-AWQF-AMV09LT-&4?GJ2R@N;!?=D0,!L23T&L ME&U9_P8MN6 ,HSK1@F]UO8OD57=JP4E 5W5C7RO>SKE4 QL2^QLL8%*YBDP>G3=.EY/G4,;H$?KW?^9 MC4)F)_E0F.E$AP%,\7_YA1(V\M=>:^1?36VSW9!M=0N/HI9$4;%1I"FMEN2C MXB-);1\/2:=@7\]E0/_XP6HMP'H;[;-R%>9Z0YX,64G$:D9;(K:"B-440]>* M=U*P1.^^T&M99D'16_U8MIB:P^P@Y&Z#"U@,"X5!+NJEALR/H_5JA#S34D[R MK9,\!=W\(0[L[["ZX8CYD7#;L1?\^]3.3FA:LN=ZP5'4TG?)GLV/ -KV MA"B)H0-CR-#TTXD9'2V;1.RB=.KS*6$&B?Z6#)+RZIBZTC"E05UT)!G2H"XX MB@REW6I()!4<2?JVVH TI[<"L&AQNT01V$7=K%JTTE ,<\<,IL($H_=H350- MO6W#D,BM*G(MI=G8-I%$HKY(]KK_8_&@H:FM; M?BQ9WIXDY=,@Y6:[J!F*DI E(6]#R""3=W2?2%*6I%RDA1M*0]O66#]PWG@Z MD4V.03Q4.N[;#KV3LZSN+%\[ J421BJ>*7CCV][8@3%_T+0&'B6,A\E06(S' M0HIVJY-OK, CT' Q#@@E]H#Z?89GXWF,1HS$+!SR1D9X_)LX) \;,43N2WI8 M'ELX>8)@#_2EQ^051E[(,4HTQBGXEO#DRH4$%<+/! S&\>[529N&4N48Q1GC M%&*P0J]=__/*HU%4HS;?I3SZ'(W=.,V"CG@:-.YKL)$%L#)WQ_YZY5 (@8+H+[-,GWIQ JP=Q.$,M=5HDFB:4F-KRJK+PJ. MHJ-STBL[L>-&(X].+OP "YG6858^.?ND= >)GU]X0()VJ>\$/FHYTM]32MNN MXF@R--E*N> HDIQ4"C0=E9.D8T'\O W\D-GC,(1%D5$8O$P ''Z,9P.FB0,G MZF*01>DE0-+1S2*)ILUR'5NR,+WH2#HZ+YV")?QJV33-KMEN-TW#;E#;L$Q;=>B_ MM,99^M(@JU,:T3ZK\2*,&NW%++R@WC.=1+-S'KI^+;_:56O+0=X&PXZ%<-L= M]@GUXI_/O* ?4*U%ZW^-^B"30GOAT@Q8&X#,RR$-^_#M!&9+&H?R+XK;R:ST M=G/T9N[TI)WNLR38V MHZ[7RDS7>*,$TQUI\VHNW;R^W/QV_6?G]K'S^S6YNKO_>G??>;RYNR6=V\_D MX=NO#S>?;SKW-]V8'ONUZ2;ULT".\"]0MB['2-A@R+)W-FD/E M+F.E[)*F45]+#BP^XH4;P]?L30I@OOET[+BP](_+UCVWLVGFFIK@5QWO[RQ>/O!S\CX"7@5\OE(%O4*]:6= \N"\; F9#XBF(!;@M MZ]_X)!X$8QC5B1:JX)99X5L8- 4G 5W5C7VM>),2XTI!3M^'\*@J<"19[8>L M3B'%*U-)7:&2GGM!M"B)7UOQR;HJ*]92[+QA-2I[A+PDXA,A8DU1K98D8TG& MY29CO2EI6-)PN6G8- LHB$\A3;0S31#=O3GB02/TC[-YF-?VQ=H>)HVJK]F\2.9"*)IKS5$)]MOW:2%6WO)SV25 MHDFBZ7@MQ"2*3HV39 NQ=WI2 E8"MEQ/2L!*P);K20G8XP"V0AYOV6M+]MHJ M,9*D,[44:)*]MDJ I*/STNGXO3L;'(RY[%A,Z0Z73KSBH4G3=FS,(E$D.4FB MJ2B<=*#:)+'KYCJ )._7\.$+K<7Q?0S@KSSL8:^3:=2M#6:SI'\-)J_6C/J2 MEB9=F#<.P$_BGFM,(U57:6$4!DW;=]>7*)*<)-%4,$XZ4+%#816%1_I"W.&( MVCP;?$G?[!(I#/I;%(;R*MKG#:W41V17'3V:9DGT%!<];6V+0E*)GL-SSW'0 M(_,1BIV/4.CRTH532+)ZNYB^O"7W8&7Q;QEY6U=4?<=(ZF9P*)'=5BW$&I9$ M:_70:BAJHRT16T'$ZEH1T7H*C2AF^A[/-)E;VI?BM:6_@2P+!YI=3\1X;?'% MYD5-,9IO.W7LR$+V%7M54G#5*?B\I1M;F^R2=B7M%F#5H.*:;SMM2%)P47!Y MFA1\KFW3&/$@M+OBI KK+2=5+&VQO>2(KRT&DM_8D&[)+*BXH%1>P([ND8DG%AZI[D,0LB;E("T>1O'T+\*H< MDE'"^* M NQF#+;KLQL/DE=S716CU]. 2@DY_2/)-89R(X(&,,#))P IPJ+8'7*H4-\? M4P]=_@0;0)->$/(G)F#J1X3Q9,__&ON,&*I"=%4W.;@Q\TP!C$0C9J/A[4TJ M"D;C(UE6WYE"*>8IPPB1R'TAPX!GR+*%#%D.+P37V$.8NSX17T7XXQF3?99Y M6+A3)2+!.(YB&!?)/>@1S5!T7>,?@C_5ECX+_'I%H6]^)'_0"?&#F,"T=:W/;-O)[?P5& MO;O8,R;%E_6RK8XK*STUB>V1E+9S7SH0"5EH*%(!05OJK[]=D-1;BN3(ENPZ M,TU% L0^L+O872R0\Y^&?9_<,Q'Q,+AX9^K&.\("-_1X<'?Q[K)5:S3>_53] MX;PGH1MT#:**SX,O%[F>E(-*/O_P\* /.\+70W&7MPS#SF-SAT8LEW8?1GRF M]X.=]37S?WSZV')[K$\U'D22!N[X*X]-OE+C1\S5[\+[/#3 MY:==>1#J4'; M#(BL+P\ &?;'S\V/>2EH$'5#T:<2"(41S%/-*&FV.483@/ U9,TAN(PDLUPN MYX?(J2GDE@^Y#C/+T Q+,ZTQ9@L,GX&'K1-XJR@P[2F8JGO%IS#%.19HGUNY MZGF/4:]ZWF>2$AQ!8U]C?G^1JX6!9('4VJ,!D.XF3Q?YY.5Y/AFZ$WJCZKG'[TDD1SZ[R'D\&OAT5 G"@ $" M?%C!CDPD/[GGL4#]A/;KN,\$=Q/X0]EDW8NJ0< ;E0#[ 3U M&X''AA_8*$>X=Y'K:I:5JQKPI^243:=PGI\9=0L@EWT6>/"??._3N_'@=J[: MI7[$%L;-SQ(B6)<)4"X6+>$_3F,E4LH D(F:UHH$KE_D(MX?^"AXZEU/(&(S MK-:'D0<3H>!-@*0PHS 6ZDE)>"6E3N&.U&7OF>)?]L0]?.YR)HC"B2W5KUKC MPRQ?YS^N9J]F1Q\ >T(O>P*]$O**2E9%>C3#U%!XYMO&:'HKNF8MV7,&)#]# M=\:D,5?R4W*7!^E,1!2YPTM6V2EUZ:E=MHL.8XQ:U"YU748+ANO9=O=/Y-[D MFU2L^SS0>HS?]62E: WDV0/W9*]B&L:_Z/ M*N_:O ^R=\T>2#/LT^#=202F!X (WDTZ1OQO5C%+@+5Z?$C)@''0=&1DF1;2 M\OFZT:Y?D5;[LEUOS1(R1<*A8-NJUSXW&^U&O44NKZ](_8_:?R^O?ZF3VLVG M3XU6JW%SO4<2K&^14+2!A-]IU(-568;!";G2:SJQC%.GO$>TC3FTG:5H_^=' MLV"<_;GVSR$3H<0G(2)#>^\WVSV#U9XG8T,!UB^9OVZ39KUVYMF^^#MW&TLHI@&DLB0M)B+7G$B M J9-0D',TR/OF(1=(GL,VV/!)0?H]:'; X^*D4M78K-9MIV#IQ4]%D2VR0:A MD.0H>V84?!862<+N 3TB5#/SCBN/, &WRA&J)^Y1CB2A!K@W0UGQX(W6AR%Z M^)GFT9$V M :"\;.;:[Z*PUB<#R(;9P0=+L6W=PW^_$D]@/YXA &R MO(:63"8AWOK8>%__[?*Z?:E-"_;ZWRZ%\3:!1E;SMJC^A"B!,5! M-"!BS#E"(Q(-F(L!F4=X0+B,")A*L"?B^. =K^]3'9S-59,D:<=G6?].*" " MU( JGPXB5LE^G&5)BB1YHJF/SF:E!P'<,R&Y2_T4B(*7-*?Q7[FL%XIE5 $) M@:;T,L!I=*@#K?G%]W9!MT_+2YL,W=SR?<&PM_IB%5(F#&47]C74T].'3"^L M'RJO)C&92! 5%,*+G)W+.J>& @S)D)C+Q&]!7L+!\YL-XS$6N1&XH0!G1"4K M6Q+\AUH8!U*,:J$WZUQ@\@+S-Y(-1'B/XTR\"@<\'^;3!RJ6),U2E9;>M]AK M('/3:1IW*_P39N$]]QET[H A2SEZBHDX4[-/"TYQURS]1PAVFPX;:=[25<(] MR]]"KEK&O+SE.$5S+8-W;1N296377)Q/.BRLOHJ)1TK#,>H*(=H2Y"\(MB*/ MJY@,O R5P^33%D%U%7=K M\/-&M,.'L5M2AL"2]?C.6*VLYXVX!?^'JZWC#=TCT\A5/TO:6YR*Q^%Q&P(@ M_W]\D#AI*1!,!SN&8Q_0A'_3H"2A;DH6QKD# 9SE ^H3-F1N+/D]AK]@6EAT M L&NZ\=H*,G?? #<\MCJ@'?*JI0.R*H<;3[E*,^7@M&92;9@DHT%A^5X"TGZ M&,(RVM+)Q4#9C0Q&:9);>140RGPV00A+,K=3K\T;[$91' M)$HVIV=/V-=ZS/VB,OIT /80M!K]SDXX)!WFAP^$)^G^]V _24G[0+K<1[7F M$>BX9(''/-PMB'@_]B4-6!A'_HA$X%Y$W9'Z,OT@[,!,I9YJ,N14HBR&<02A MP2AKZX8^ ,?OT$9S=.BB#5-.SYY@ E]+-Y+(9YL,4TDO&MLEF%:.5-:-\OJ< MS>-#(TS#+O?OUR9U-\WB;B[UER"9/OD<<%Q-R*?6H\5^RR#U=\$E"#I&%G&0 M.L[1HD/1"4._0T%J)>C.V%([N E2+CK.V?J]FPT"DT.>FUU9)#4U*<.!%],< M)X.ISIX9C;C\1MR".S2&KOF\2R#1TZ'B]A]YM./%HG6J'/76!V M]]LTTH_"F&5O/#W!=.V'0.KN)9!FY:AN6AFL: M>?1K(MGD$Q5?F"0?/]:^IX8A72!P00$VDP@B0X]D/#N$2=AL8UH9@:3:VNT1 MUZ=1M#M9?"T\2C29)*I\%.VPB.&5<.@ZK;A50L0RMQ36DH<>AS<3+^[1)0Y[ M+9RIYFG7FJG9Y@+7+6&N4A =6 M1[,V/!$R'A1#A=(]A9?/NH2H>,DE\4(;6$C@U#6\O\9FB[ M#ZE.+- 5P%@\EA9YQ8!\ MW<"CPHN2O4YO5=1I']%QU#FM8/H!J,=87%=(R/2Q[$&8L*XBF$^Q;&3AH/9D MG5*1K3'YA'9@L8KEXB??.MN=_-T3DY7RCFD=P>@7C7;!^%2H_T!'$:Z93W.B M?+%^X9FU9GF52T.R/K%TPTJE:/'O)HMB7ZJ2GQL0]C13!")+WH^EN1:"=F&# MOD7]QK*Z']!2\#$J=F%O9N0F(.FQNX3\[.S=B=*[U)##FAO%H*<45!;+H4"2 M&04C08, M-I5!1+ LHFZBY2):"9P'-D3C"DF1GQ(U#E L#K*MEPQEV$I3 K> M5.!MG5R"?1F,"R1JVD/L68,]]YJG?YIF:83#?8+&8TIFQ^2YMZ">= MX(S1?B(,1_A!"F:Z=9N?.>^I#39"@LYY>M$W308=GSTWI"'/N.!6!A M?#);V8[7M<1@KQ&#* ;//D'A\<+Y_+;6/,UL;5DWS)6V=F)150$KIN@34YMJ M.LYN1+-TN;)<]7T5> M\50O6>N'6IK5VNB B=HT.Y3D88*8Q]S4,E64$<1>N6JVQEZ'^K.D5;?9H-SV M:/5>;,4ZYEZQR!5\@*^W.%B^);E+W?COV^S?F_0N3YBA_[=[X=RM#(_/2XW# MJR5T>0)#?4,0H^;G 7I=' GU^M[LAR])[L MJPH <+>:XSA!A3&=T4QP R[7>9Z^!FI_?25TS-X#\TJ(_%:R)E)PKP2HK)<$K'-5T)1F@U3U#RYI_8T9[*(!2;]/\[&(R<]DD/'MML%DN;9O:G\P!**_NMB>,GJW; MAA[C%GZ3K7**Y$7XF'@O;64++S,EBDSH/&@7SI^WGTB,D[Z!F; MOUTVNTUVVL.;QNOI,%D)\KE8D8_RI$:%3RYU_CX(%@YO MHCG;U$EO81/W1_B;/#T)6]5QAJ==1_3? MP5+_>%;U_U!+ P04 " "\@#Y8T4<'D7," "&!P $0 &QF=FXM,C R M-# Q,S N>'-DS55;;]HP%'[G5WAYGG.!M %4J+16E2:QK6*MUK?)<8[!:F)G MM@/TW\\VR6AZ6Y'VL+S$.>?[SOTX9^>[JD0;4)I+,0N2, X0""H++E:SX/;F M"H^#\_E@1J/"S:<) 7] MN)JF8SK.*1OB$4DSG*;D%.?#[!2?G#"6T>'I)*:9-[K34TW74!%D4Q-ZNM.S M8&U,/8VB[78;;D>A5*O(^DJBNR^+[QX:M-B2B_L>>I>KLL./(J?.B88_<+81 M/7C)&6R(,&0%(955Y#*.DY$M*C%&\;PQ<&5+,?' MX(UIH.%*;J("N.OH5K(&93CHQSOD#:P5L%G@-@EW4_NS)'EH(^D@ MSQST6^#4D:5 N3ADTG'-0VVYVC:@A'UM_N?$:P7')FXIVMX:OM%'YN_X-U:/ M>#$++J3]"US;"R1 3GZ[_/SF#>-]'SB=X ML%_S^> W4$L#!!0 ( +R /EBY:5Z^K H $1B 5 ;&9V;BTR,#(T M,#$S,%]L86(N>&ULU9U=;]LX%H;O^RNTV9M=8%B+'R*IHNV@FVD'Q6;:H$DQ M@UTL#'XF0FTID)4F^?=+R79BQY(M2K;JWJ2.0Q^^YXV?0QY13E__>C^=!-]- M/DNR],T)?!F>!"95F4[2JSH5X8I+91' @C! B*! (D9! M%%G+%*)QJ%@5=)*DWUZ57Z28F<"EE\ZJ;]^<7!?%S:O1Z.[N[N6]S",X'E4_?1PZ2^H&NK!P]-/C5/&HW+$*#57Y>_VW.1)IB\*D1=G0IJ)4U]%*QYNS)N363*]F9CE M<]>YL?5A)WF^%K54&9Y-[ MZ2J$.;S@E6EZ2YZ_H=ZG>JCW[N-4O:4?7O&^WA99(28#O"V>IEF1/"F?.'./ M%M.4@;84TVJ>1>E>D6KN"Y-J,Z^6:Z+\Y<8_&VB3C"Z-N\Z1X>'^OKD5Z M93Z)J1E+126FTJU5%KNER^H(Q(PQH!C6EB)HJ-;CXO$]/38I^'JQG+Z:8_L$ M)QZ9%0V$YF:6W>;J:6V;3NH6++=6E:L;'Z5NWMF-6+S J2PW G/A;Y<:@Z7( MH%3Y>O243P<3)P>W9G)4KF1J3L9DYUE??,J)=7V?>1 M>ZG+'^'R 2@?5#0U!AQM_-K>Y4N5(E<[/%Z,&*G,[7!N"K!FM\VS:;MTBJS= M;WQNFYOT),AR;7*W:ZU)H/9]!Y&\3(J) Q<+;; Q(,1( 2(C"[@V$3 P%EI( M32/E#>XR^+%!6XD*,AM ] _YSV IUY_:1_?:$]O%DP/3ZFM')UR?Y]T+U<=@ M@V/Z/(TZ1#?&^./YIXOC%N'3;#J]39-Y5S0;8Q%3"ID&3(?"+:ZA6UP)A4 ( MM^HJQ)FDJBVCM3,<&Z@+D<&ZRO:YAR86$]?O(#=FGLG:NLC#H;N MUH16^=T^T!_B\G+&Y/PZ2\VGVZDT^3BRC$22A4 *'0-"< QBSC% ',&8*4NH MH6WY?1[\V-"M] 65P&"NL#VV&\;M)K:/'0>&U<,)+U";4N[$Z$:PP?!L2F.5 MS,8Q_E!>YJ*\DGOQ,)799(Q"9B*,.."(NUVO<2LJ5VY%)9@0JA@2*D)MB5R+ M?&PX+L0%'G4TX]!ZW7?Y> -;FVHF^]4B#H5>;P"IW]0/\H7N? M%FY?_#%567Z3Y=7">E&(PIQFMVF1/YQFVC6@D4!$" @T#S4@E L@C>9 QQ'G MQ&)A<-@6Q1;S'1N@<\G!FN9?@DJULSE8* ]*Z>WI;>/[;J;W[.:!2=^'D5YE MP,.>3L6A3?S!2H9'LJN%Q.=E7. "L3V]SEO#?CXVQV:_++\E@K_VRM M:RFM)LBXW3^ BKNRH-V>0X00 2YCC2%#,&Q_4+5KLF,K#4XO4"N"@[GB8"XY MJ#2WKPX[K=Y=(?9IX(&K1"_OO I%6U,Z%8N=P0/M ?Y-/LN\G? MR5F1"U6,51A%$=<,:"(0((AA$"L; 2@(YY":$-O6 *]%/C9P*W'!?Y?R_M<> MV'7#=H/:V88# ]K: 2\P:[/M!.1ZI,% K$U@%<#Z 5V[\?=3DU\EZ=7O>797 M7+O5^D:D#V,F+14P%B!4"@,BL0#21C' V!J"$$4&$K]FO':>8X-RT5HNM09S ML<%"K6\C7F]MVSZ\MV'#M.&^7G7HP;^-;G-!GS[\-[]]VH[ M2&**8(P(P% 2UWE+#KBQ$BBJ&0Y1)+2!'3OOGZGGWDNSW:O-_DD:[(-WU@?J MJ8^AF_;KH_?305]DDT0EA2LF?[@=?)Z(R=@B$FL1(X!I% $"A04<8P,HC3GD M%"+)6R._&?[84']2&"PE>MQ:NNG>;K#[>7)@H'WL\+NUM#'K;C>7;H8;[O;2 MQE36;C!M'M6A/RXON^=&5(? -"3&YFEUPN/$>1ZDKYG5HC7N:,&A.^-VV?OUQ36I=FN+5P,-UQ77R%]KBNM^ MWO.$^CR;%6+RG^1F<=^+8AQ2#:1@L$3/@CAT"R0*(8NY,BH6GBUQW33'!N+S MP]:YV,"I[72+2ZVS;3OBOGX-TQ![6]7]5+K6B?YGTNMA?\R)=&UJC>?1]:.[ M'RI=NI>.0XD%UA:#B"H+B$'EC6[8+;U"424H=E];W^BV&OC8$'\\*"G%^9\; M55ZU/R[R=6"H4Z*MR7)4!5H\(.@5?EUYS]K/_='[9V+HP-7FVHFX]4B#(5>;P"IS]0.Z;F]/7:!<3#ZFVMS_VSR,)1,T MA!(#9#D"1*((2*0,8-H1R:0DU#*_G>VS&8X-PL5.;:$RJ&0&3J?O;O:YD6TW MLCWL&68/V]Z9#IO7ANQ[[%N?1QQXR]J0T.9NM6E@5Y _))/E)^^08"K&&@(D MRH\ M]+].M!+SQUPDVDRJ\0I1S="N@%^*^X_:K>2)7?SM@<5* N.06VAB$(7EV8S[ M"@1SK#,-I8PIE9#$?I@WS'2DL#NUP;K M9: I\L#%8$>"FR5AUPMZKOR+?\Z2U, QH3%$-N3 6!$# FWDMN0( JQ,S.*8 M,D-DI[5_=98C+0B/:]OB05"*#3ZG74^-UHSUW -TM6O@74!KI[KO!.J.MW&Q%J* M=%'TZ>W3I*V=\=B394RFQ-Q8$@2B&W]_ M!-^MT/]YMB=@OU-J_*XSD[I/,9 ME*&*>;DZGO]R]8&8^0\G!P?O_D+(;W__=#'[L0HW&RB;V5D-KH$XN\N;]:Q9 MP^S7JOX]OW6SR\(UJ:HWA)QTEYU5UP]UOEHW,TYYMNNV^[8^\F#!"YV(YI22 M+ I&3-*.:)]1$Q.W+(:_K8XR$XP/B1/A,DVRS"GBN59$RI1TX,K2H+M!B[S\ M_:C]X]T69CB]]$ MUYM9:Q?=MW]TW>:O=<1AV>*WGRX^AS5L',G+;>/*T!K8YD?;KO&B"J[I5/]3 MOV;?[=%^(KMNI&TB#"5BA_?;.#\YF,T>Y:BK CY!FK6OOWPZ?V:RR!/:Z^*-M74,ZGA?IMB1M:"D3M+7[ MUR\7+[ZX<%W#%KGIIGR!#4]CM-;>[ [<-U!&>)SISE!1A6>=BE;GJMY=63@/ M1=>ZC) ONY%/_;:I76B6P40FM+F9(QD$1FSBBJ90)*:,N6/U\]JWG6W2] M"\L6PN&JNEW@P!@>+MHWK32BD^6%N4=YWN;W[G=XA7V7,3@1),W08^9(YFDD M3LB(IHU2WE'AA1OD]M?6GGO]=5A/ZS"KZ@@U+B0[/$8E>].KIM9@\LK=#W'B/@E MU'D5WY?Q1UQ_EU;X1*G/"*6 *C"<@)54$I5"A& ,C1Q&"?TSL[T8X--GX.U: M[AF&]V63-P^?8)6W2I3-SVX#2V\3\&" Z. 2R:0(Q,0 *(D.T1IM* Q;O5ZS MV@L%,5T4!BLY"1+.4*O:%>>X&][_$QZ6DL>81>>)-P+54 +?)1M(I,"D,CB' M*$9 X1NSO5C(IL["$"WW#,,I+FJQ7=@^%&ZU#$Q$Z3TCF6XW-XBXN7&&4$OF MK.*&,FL&0?#,7*_@R^D&_^W:36(%.,>LK;ZNZD[QSR@\G%4W"/+#615Q01-, M1ID)PHWA)$LF(UXZW-]L= XS*NL9'6$]^(].] )$31>0L76>!#8?\@)^OMEX MJ)=@,-4&R8B%@,AS%3$1MXY$QU CEZA); 1&OECL!82>.A!O5' 2T;]R]^<1 MM)J(QP.PYE$0P55 C)DG1ME$@&&Z1)V4N!6.@,)WS/?BPDR=BS&T MG00DIS%B"+9/+Q=Y"6R))Q\C%8\D6&?Q3*02\5$'PF+R(60>9VA' .05T[W@ ML%.'8ZBF$P6#+YF4%FQ$6;AK91&)&-;N@HXQZJ)EROK_"1B\7UV*_O^1\=^) M.B4RSO#MQ_JJNBN7*LNHU4BSE0*W1@.).)$EHEB;/GFOJ<_&X^*+X7Y43+A< M.8:@4V*B.S)_K"_KZC8O RP9#UQRZ0BU%G4!QHA77!#(I,J4230*/AX8WUCO M1\>$"YFC23LE1"ZK;>.*?^7774JE@U.044.$Q!TQ\]82FV6:*$7!*JJ\T"," M\LQV/SPF7]P<+.N>X6A7O=,:7.=WU$X([301-L-3DFL+,VUIUJG(T&_FDPC# M;M%]9:T? !.N:+Y9NCV'O+TY7ERNJW*76K,455 ,3\,)L^J,18,")$6DT\9I MJV6 8:O MQ;[A7["]=- >59M-C?E4_J\72;P/')O<#_S>.1A MEA)'-2Y9+"2M+0A)U2 &7C7;#X0)URV'B[EG&CY711[R)B]7/^$!I\Y=L82H M3<)#+_&"A_;F/>;*0EE".9Y],5N2U@Y+)U[:[,?!A,N5 V7<,P27-;0$ QYL MNZ;:""F2&%:,^K[M?E!,N%8Y MDJS3@N-\N[V!^NNY, 9 C6:$,RH)IPL7*0A'L._U7MVN>;/S]L?%4LO;&41H;G8(L^9]QK8BQ^5'@P"AHT M5RD.BOTS<_T"/^%ZY-O%F\B/_OU]6+MR!=V#7@X$,PK7*T@2'-D4$L! A0#% @ O( ^6+EI M7KZL"@ 1&( !4 ( !%4L &QF=FXM,C R-# Q,S!?;&%B M+GAM;%!+ 0(4 Q0 ( +R /EB067TPWP8 HS 5 " M ?15 !L9G9N+3(P,C0P,3,P7W!R92YX;6Q02P4& 4 !0!, 0 !ET # end XML 17 lfvn-20240130_htm.xml IDEA: XBRL DOCUMENT 0000849146 2024-01-30 2024-01-30 0000849146 false 8-K 2024-01-30 LIFEVANTAGE CORP DE 001-35647 90-0224471 3300 Triumph Blvd Suite 700 Lehi UT 84043 801 432-9000 false false false false Common Stock, par value $0.0001 LFVN NASDAQ false